OraSure Technologies, Inc. Overview
Pro stress-test →OraSure Technologies is a diagnostic and medical device company specializing in point-of-care and self-testing products, with a portfolio of oral fluid and non-invasive specimen collection technologies that support detection of infectious diseases, drugs of abuse, and health biomarkers. The company's flagship product, the OraQuick® rapid HIV test, was the first FDA-approved over-the-counter oral fluid test for HIV detection.
Strategic Profile
Pro stress-test →The company reported Q4 2025 revenue of $26.8 million with management pointing to early signs of stabilization across key end markets after a transition year marked by a challenging funding environment. Executives highlighted two mid-year 2026 product launches as near-term growth catalysts, following FDA submissions made in December. Entering 2026, the company is seeing "increasing signs of stability in key segments," including improved visibility to funding for testing and research programs.
Competitive Landscape
Pro stress-test →QuidelOrtho is identified as one of OraSure's 46 competitors. The company competes in the broader in vitro diagnostic testing market with point-of-care and self-testing products. OraSure's competitive advantages include its non-invasive specimen collection technologies, flagship OraQuick brand recognition, and expanding sample management solutions for genomic and precision medicine applications.
Industry Context
OraSure Technologies, Inc. operates in In Vitro Diagnostics (IVD) / Medical Devices - Point-of-Care and Specimen Collection.
Key facts
Founded: 2000 · Headquarters: Bethlehem, Pennsylvania · Revenue: $115.0M (2025 full year) · Market cap: $194M